Wegovy Titration Week by Week: What to Expect

The Wegovy label prescribes a 16-week titration — five doses, four weeks each, reaching the 2.4 mg maintenance dose at week 17. In clinical trials (STEP-1 through STEP-4), roughly 83% of participants completed titration. The rest dropped out or slowed down, mostly because of GI side effects. What the trials don't always communicate is what each step feels like. This post is a week-by-week account, drawn from the trial data, FDA prescribing information, and the practical experience of our medical reviewer.

Why titration is slow

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a natural hormone released after meals; it slows gastric emptying, enhances insulin secretion, and signals satiety. Semaglutide stays in your system at levels that keep these signals "on" for roughly a week per injection. Flipping that switch fast causes gastric dysmotility — nausea, vomiting, constipation — which is the primary reason for the phased ramp. Each four-week step gives your enteric nervous system time to recalibrate before you bump up.

Fast escalation was tried. In early trials, doubling the step rate roughly doubled GI dropouts. The 4-week-per-step template is a pragmatic minimum, not a conservative ceiling.

Weeks 1–4: 0.25 mg weekly

The 0.25 mg dose is below therapeutic threshold. You take it to acclimate your gut, not to lose weight. About 20–30% of patients report mild nausea in the 48 hours after each injection; fewer report vomiting. Many feel nothing at all and wonder if the medication is doing anything. It isn't — not yet. Stay consistent with your weekly day; pick the same time if you can.

What to watch for: any sign of severe abdominal pain (call your prescriber — rule out pancreatitis), uncontrolled vomiting (possible dehydration), or allergic reaction. Mild first-week nausea is normal and typically resolves within 5–7 days.

Practical tips: inject before bed on day 1, so you sleep through the peak of any nausea. Keep bland food (crackers, rice, broth) on hand. Hydrate; GI effects accelerate dehydration.

Weeks 5–8: 0.5 mg weekly

Appetite suppression often becomes noticeable here. Many patients report feeling full after half their normal portion by week 6. Weight loss starts trickling in — perhaps 0.5–1 kg over these four weeks. Nausea typically spikes for 1–2 days after the step-up, then fades.

This is the first step where the medication is doing clinical work. It is also below the target for most adults; don't expect big changes yet.

Weeks 9–12: 1.0 mg weekly

For many patients, 1.0 mg is where things click. Portion sizes drop noticeably, cravings become less urgent, and "food noise" quiets down. Some patients plateau here and stay at 1.0 mg long-term; the FDA label permits this if higher doses aren't tolerated. In STEP-1, mean weight loss at week 12 was about 5% — modest, but the curve gets steeper after the maintenance dose is reached.

GI effects usually return briefly after the step-up, then stabilize. Constipation may replace nausea as the dominant complaint. Fiber and fluids help.

Weeks 13–16: 1.7 mg weekly

The second-to-last step. Some patients find 1.7 mg their sweet spot — strong appetite effect without the side effects that a small minority report at 2.4 mg. If you're considering staying here long-term, talk to your prescriber; the label explicitly permits 1.7 mg maintenance.

If you're tolerating 1.7 mg well, the final step to 2.4 mg is usually smooth.

Week 17+: 2.4 mg (maintenance)

This is the dose that drove the 15% average weight loss in STEP-1 over 68 weeks. Expect continued — but slower — weight loss from month 5 onward. Most patients plateau around month 12–15. At this point, the medication's role shifts from weight loss to weight maintenance.

GI side effects at 2.4 mg are usually mild by this point. If persistent nausea, vomiting, or abdominal pain appears months into maintenance, that's not typical — call your prescriber.

If you need to slow down

Slowing the schedule is common and usually fine. If GI effects persist past 10 days at a given step, your prescriber may keep you there for an extra 4 weeks before advancing. This is standard practice and doesn't reduce efficacy. Do not self-advance faster than the schedule — faster escalation is associated with worse outcomes, not better ones.

If you miss a step-up by a few days because of travel or a missed pharmacy pickup, that's not a crisis. Advance when you can.

Red flags during titration

• Severe, persistent upper abdominal pain (possible pancreatitis)
• Vomiting for >48 hours or signs of dehydration (dark urine, dizziness)
• Vision changes (possible diabetic retinopathy progression in patients with pre-existing retinopathy)
• Yellowing of skin or eyes (possible gallbladder or liver issues)
• Rapid heart rate at rest (unusual, but reported)

Any of these warrant a call to your prescriber the same day.

Sources

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). N Engl J Med. 2021;384:989-1002.
2. Rubino DM et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP-4). JAMA. 2021;325(14):1414-1425.
3. Wegovy (semaglutide) prescribing information. Novo Nordisk. FDA-approved label revision, 2025.
4. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP-2). Lancet. 2021;397:971-984.